Referencias recomendadas 2010

Gliomas de bajo grado

Metellus P, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010 Dec;120(6):719-29.

Kim Y, et al. Molecular classification of low-grade diffuse gliomas.  Am J Pathol. 2010;177(6):2708-14.

Houillier C, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560-6

Tabatabai G, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 2010;120(5):585-92.

Capper D, et al. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010;34(8):1199-204.

Labussière M, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74(23):1886-90.

Camelo-Piragua S, et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis.  Acta Neuropathol. 2010;119(4):509-11.

Soffietti R, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17(9):1124-33.

Chang EF, et al. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. J Neurosurg. 2010 Jul 16.

McBride, SM et al. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010;97(1):33-40.

 

High grade glioma

Kunwar S, et al. Phase III randomized trial of CED of IL13-PE38QQR vs. Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010;12(8):871-81.

Wick W, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168-74.

van den Bent MJ, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597-604.

Brada M, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28(30):4601-8.

Li J, et al. Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 30.

Sampson JH, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-9.

Linfoma primario del sistema nervioso

Thiel E, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036-47.

Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010 Feb 8

Ghesquières H, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol. 2010;21(4):842-50.

Omuro A, et al. On behalf of the ANOCEF Group (French Neuro-Oncology Association). Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J Neurooncol. 2010 Dec 19.

Juergens A, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67(2):182-9.

Radioterapia

Amelio D, et al. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues. Radiother Oncol. 2010;97(3):361-9.

Wang M, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys. 2010;77(3):662-9.

Lawrence YR, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S20-7.

McPherson CM, et al. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro Oncol. 2010 Feb 14.

Quimioterapia y otras terapia blanco dirigidas

Perry, JR. et. al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28:2051-2057.

Hartmann C, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1 mutated glioblastomas and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica. 2010;120(6):707-718.

Wen PY, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
  
Stupp R, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712-2718.

Calidad de vida y soporte paliativo

Rooney AG, et al. Depression in Cerebral Glioma Patients: A Systematic Review of Observational Studies. J Natl Cancer Inst. 2010 Nov 24.

Sizoo EM, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol. 2010;12(11):1162-6.

Taphoorn MJ, et al. Review on quality of life issues in patients with primary brain tumors. Oncologist. 2010;15(6):618-26.

Lucas MR. Psychosocial implications for the patient with a high-grade glioma. J Neurosci Nurs. 2010;42(2):104-8.

Veilleux N, et al. Quality of life in neurooncology--age matters. J Neurosurg. 2010;113(2):325-32.

Metastásis cerebrales

Kocher M, et al. Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. J Clin Oncol. 2010 Nov 1.

Metro G, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2010 Aug 19.

Patil CG, et al. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev. 2010;(6):CD006121.

Niwińska A, et al. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer. 2010;116(18):4238-47.

Thomas SS, et al. Modern multidisciplinary management of brain metastases. Curr Oncol Rep. 2010;12(1):34-40.

Marko NF, et al. Radiotherapy: Neurocognitive considerations in the treatment of brain metastases. Nat Rev Clin Oncol. 2010 Apr;7(4):185-6.

Suh JH. Stereotactic radiosurgery for the management of brain metastases. N Engl J Med. 2010;362(12):1119-27.

Mahmood U, et al. Whole-brain irradiation for patients with brain metastases: still the standard of care. Lancet Oncol. 2010;11(3):221-2.

Meningitis carcinomatosa

Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11(9):871-9.

Mammoser AG, et al. Biology and therapy of neoplastic meningitis. Curr Oncol Rep. 2010;12(1):41-9.

Glantz MJ, et al. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116(8):1947-52.

Strik H, et al. Diagnosis and individualized therapy of neoplastic meningitis. Expert Rev Anticancer Ther. 2010;10(7):1137-48.

  
Síndromes paraneoplásicos

Vincent A. Successful 'passive transfer' of paraneoplastic stiff person syndrome with antibodies to an intracellular antigen. Brain. 2010;133(11):3164-5.
  
Giometto B, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67(3):330-5.

Niehusmann P, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol. 2009;66(4):458-64.

Titulaer MJ, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol. 2010 Sep 29.
  
Graus F, et al. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2010;257(4):509-17.

Titulaer MJ, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27(26):4260-7.

Kayser MS, et al. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry. 2010;167(9):1039-50.

Titulaer MJ, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol. 2011;18(1):19-e3.

Neurotoxicidad y radionecrosis

Levin VA, et al. Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. Int J Radiat Oncol Biol Phys. 2010 Apr 15.

Soussain C, et al. CNS complications of radiotherapy and chemotherapy. Lancet. 2009 Nov 7;374(9701):1639-51.

Myers JS. Neuropsychologic testing for chemotherapy-related cognitive impairment. Adv Exp Med Biol. 2010;678:55-69.

Neuropatología

Metellus P, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120(6):719-29.

Hartmann C, et al. patients with IDH1 wild type anaplastic astrocytomas exhibit worse. prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-18.

Rodriguez FJ. Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol. 2010;34(2):147-60.

Behdad A, et al. Central nervous system primitive neuroectodermal tumors:  a clinicopathologic and genetic study of 33 cases. Brain Pathol. 2010;20(2):441-50.

Ciencias básicas

Parsons DW, et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma. Science. 2011;331(6016):435-9.

de Tayrac M, et al. A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas. Clin Cancer Res. 2011;17(2):317-327.

Verhaak RG, et al. Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.

Noushmehr H, et\ al. Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-22.

Carro MS, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463(7279):318-25.

Wang R, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):829-33.

Ricci-Vitiani L, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010;468(7325):824-8.

Persson AI, et al. Non-stem cell origin for oligodendroglioma. Cancer Cell. 2010;18(6):669-82.

Imágenes diagnosticas

Jain R. Perfusion CT Imaging of Brain Tumors: An Overview. AJNR Am J Neuroradiol. 2010 Nov 24.

Price SJ, et al. Correlation of MR Relative Cerebral Blood Volume Measurements with Cellular Density and Proliferation in High-Grade Gliomas: An Image-Guided Biopsy Study. AJNR Am J Neuroradiol. 2010 Dec 16.

Stadlbauer A, et al. Fiber density mapping of gliomas: histopathologic evaluation of a diffusion-tensor imaging data processing method. Radiology. 2010;257(3):846-53.

Raffa RB. Imaging as a means of studying chemotherapy-related cognitive impairment. Adv Exp Med Biol. 2010;678:70-6.